Clinical Comparison of the Performance of Two Marketed Ophthalmic Viscoelastic Devices (OVDs): The Bacterially Derived Healon PRO OVD and Animal-Derived Healon OVD

Loay Daas,1 Jose Manuel Larrosa,2 Alicia Gavin,2 Carlos Isanta,2 Achim Langenbucher,3 Beth E. Jackson,4 Linda Tsai,4 Priya Janakiraman,4 Rafael Guerrero,4, and Berthold Seitz1

1Department of Ophthalmology, Saarland University Medical Center UKS, Homburg, Saar, Germany
2Hospital Provincial de Nuestra Señora de Garcia, Zaragoza, Spain
3Institute of Experimental Ophthalmology, Saarland University, Homburg, Saar, Germany
4Johnson & Johnson Surgical Vision Inc., Santa Ana, CA, USA

Correspondence should be addressed to Beth E. Jackson; bethjackson28@yahoo.com

Received 5 August 2020; Accepted 24 October 2020; Published 18 November 2020

Academic Editor: Takayuki Baba

Copyright © 2020 Loay Daas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This clinical investigation compared the clinical performance of two marketed ophthalmic viscoelastic devices (OVDs): the bacterially derived Healon PRO OVD (test) and the animal-derived Healon OVD (control) under normal use conditions during cataract removal and lens implantation. This prospective, multicenter, randomized, parallel, participant/evaluator masked, postmarket investigation enrolled 139 subjects (170 eyes), 116 (143 eyes) of which were treated (73 test; 70 control group). Both test and control OVDs were used, at a minimum, to inflatetheanteriorchamberandprotecttheendotheliumpriortocataract extraction according to the standard procedure. The surgeon completed a postsurgery OVD clinical performance questionnaire, and intraocular pressure (IOP) was measured before surgery and at the 1 day postoperative visit with Goldmann applanation tonometry. Any IOP measurement of 30 mmHg or higher was considered a “spike” and recorded as a study-specific, serious adverse event. The bacterially derived Healon PRO OVD was found to be statistically noninferior to the overall clinical performance of the animal-derived Healon OVD control; thus, the primary hypothesis was satisfied. There were no statistically significant differences between OVD groups for any of the additional endpoints relating to IOP changes or to safety, thus satisfying additional hypotheses. The Healon PRO OVD showed statistically significant improvements in surgeon ratings for ease of injectability, transparency/visibility, and ease of IOL placement. The safety profile was also similar between OVD groups with regards to serious and/or device-related adverse events, as well as medical and lens findings. The results of this clinical investigation support the safety and effectiveness of the bacterially derived, currently marketed Healon PRO OVD and indicate that the intraocular surgical performance was similar between the two OVDs.

1. Introduction

Viscoelastics are indicated for use as a surgical aid in anterior segment procedures, including cataract surgery with or without an intraocular lens (IOL), secondary IOL implantation, corneal transplant surgery, and glaucoma filtration surgery [1–4]. Some established benefits of using viscoelastic materials in cataract surgery are endothelial cell protection and maintenance of the intraocular space [1]. The protection provided by viscoelastics results in reduced trauma to the cornea from inadvertent touch due to operative debris from phacoemulsification or surgical instruments during surgery. Minimizing corneal trauma reduces the incidence of endothelial cell loss [5–11] and potential corneal oedema. Viscoelastics also impact the ease of injectability and placement of the IOL as intraocular visibility during surgery is affected by the quantity of bubbles within the OVD. The ease of viscoelastic removal
affects both surgical tissue manipulation [12–14] and postoperative IOP [15–21].

Traditional viscoelastics, such as the Healon ophthalmic viscoelastic device (OVD), are developed from sodium hyaluronate derived from rooster combs. Due to concerns of crossover contamination, animal-derived products have been losing favor in many parts of the world. The ophthalmic OVD under investigation (Healon PRO OVD) is a bacterially derived sodium hyaluronate version, formulated to have similar physical properties as the animal-derived version (Healon OVD). This clinical study compared the clinical performance of the two OVDs under normal use conditions during the cataract surgical procedure.

2. Materials and Methods

2.1. Trial Design. This 2 day, prospective, multicenter, randomized, parallel, double-masked comparative study was an evaluation of user acceptance rates of the bacterially derived Healon PRO OVD (test) versus the animal-derived Healon OVD (control). Both are considered high-molecular-weight cohesive viscoelastics and are manufactured by Johnson & Johnson Vision, Inc.

The study was conducted at two EU sites (Germany and Spain), and 16 surgeons participated in the study and included 170 eyes, each randomized independently to one of the two OVD groups in a 1:1 ratio. Participants were implanted with any intraocular lens type and could include one or both eyes in the study.

2.2. Subjects. Potential participants had to satisfy the following criteria in, at least, one eye to be enrolled in the study: cataract requiring extraction and posterior IOL implantation and otherwise clear intraocular media. They need to be willing to comply with examination procedures and to sign the IEC-approved informed consent. Exclusion criteria included pupil abnormalities, unresolved ocular surgery, or trauma affecting visual outcomes or increasing ocular risk. Known steroid response, ocular hypertension of ≥20 mmHg, medically controlled ocular hypertension, or glaucomatous changes in the optic nerve were also exclusion criteria, as were pregnancy, lactation, or hormone fluctuation with potential refractive changes. Exclusion criteria also included concurrent participation in any other clinical trial (or within 45 days prior to the preoperative visit).

2.3. Procedures. Sequential randomization according to the study randomization log took place after the participant had signed the informed consent document and met all inclusion and exclusion criteria. The investigator documented which eye would be the first to undergo surgery, if applicable, and all study personnel concerned with data collection were masked to the randomization log.

During surgery, masking was maintained by removing the packaging from the randomly assigned OVD out of view of the surgeon prior to use for inflating the anterior chamber and coating the endothelium.

Lens removal was performed using phacoemulsification/aspiration with or without laser fragmentation, and the surgeon’s routine choice of commercially available IOL was implanted prior to complete removal of the OVD. Standardization of the surgical technique across study sites was ensured by using routine, small-incision cataract extraction with optic/haptics placed in the capsular bag and sutureless incision closure. Laser-assisted cataract surgery and AK or LRI were allowed bilaterally, any surgical complications were documented, and implantation of an IOL was at the investigator’s discretion.

A validated ethics committee-approved questionnaire was completed by the surgeon at the end of each surgical case to collect investigator acceptance for the study OVD used, and the question “Rate the overall performance of the OVD” was used to support the primary objective of the study. Additionally, this questionnaire collected information regarding the ease of injectability, quantity of bubbles, transparency/visibility, tissue manipulation, ease of IOL placement, and ease of removal. Each question was rated on a 5-point scale (1 = unacceptable, 3 = acceptable, and 5 = excellent). Consistency was ensured by using the same study evaluator for all pre- and postoperative study-related subject testing.

Medications were administered as consistent with the investigators routine medication regimen.

The operative visit supplied the primary endpoint: rate of user acceptance as reported via surgeon questionnaire response.

Other endpoints gathered included the following:

1. The rate of IOP spikes, defined as 30 mmHg or greater at 1 day postoperatively as measured by Goldmann applanation tonometry
2. Mean change in IOP at 1-day postoperative visit from baseline
3. Frequency and proportion of each slit-lamp finding
4. All serious or device-related adverse events

2.4. Statistical Analysis. The required sample size was calculated based on the percentage of eyes with acceptable overall performance of the OVD (defined as having a score of 3, 4, or 5; 3 = acceptable and 5 = excellent). The acceptable overall performance rate was assumed to be 85% for both test and control OVDs. With 71 eyes per group, the study had 80% power to evaluate the surgeon’s acceptance rate of test eyes as being no more than 15% worse than the surgeon acceptance rate of control eyes, using one side of a two-sided 90% confidence interval. Adding 20% for subjects lost to follow-up and screen failure yielded a sample size of 85 eyes per group (170 eyes for the study).

Descriptive statistics included sample size (N), mean, standard deviation (SD), median, minimum (Min.), and maximum (Max.) as appropriate for continuous variables, and frequency and proportion were computed for categorical data.

For continuous variables, statistical tests assuming normality were generally used. Two-sample T-tests were
used for continuous data, and the Wilcoxon rank sum test was used for ordinal data. The primary endpoint uses a noninferiority method and was evaluated using a one-sided alpha of 0.05 (with a two-sided 90% confidence interval of the difference), and the rest of the endpoints used an alpha of 0.05 for two-sided statistical testing. All available data (Safety Population, SP) were used for the data analysis.

The primary endpoint was the rate of user acceptance defined as having a response of “3, 4, or 5” in overall clinical performance by the surgeon to the study viscoelastic questionnaire. The rate was reported by OVD groups, and the differences (test minus control) were analyzed using a noninferiority margin of 15%. The lower confidence interval of the two-sided 90% confidence interval (equivalent to the 1-sided 95% CI) was used for evaluation, and the null hypothesis was that the test OVD was 15% worse than or equal to the control OVD. The alternative hypothesis was that the test OVD was not 15% worse than or equal to the control OVD.

Other endpoints were analyzed and reported by the OVD group, including the frequency and proportion of

1. responses to each of the other investigator questionnaire questions
2. eyes having a postoperative IOP spike
3. minimum and maximum change of IOP from baseline (1-day postop IOP minus preop IOP; the preop visit was within 45 days of surgery)
4. Slit-lamp findings

3. Results

3.1. Participant Demographics. A total of 139 subjects (170 eyes) were enrolled, 116 (143 eyes) of which were treated, 73 eyes received the bacterially derived Healon PRO OVD (test group) and 70 eyes received animal-derived Healon OVD (control group). Of the remaining 27, 15 were screen failures and 12 were discontinued. The 12 discontinued subjects were discontinued for the following reasons: the subject was uncooperative/refused further participation (N = 7), the surgeon did not use the study OVD (N = 4), and another surgeon not in the study performed the surgery (N = 1). The mean patient age was 72.1 years (range: 54–94 years), 56% were female, and all participants were Caucasian. There were no statistically significant differences in the demographics between the Healon PRO and Healon OVD groups.

Participant baseline ocular clinical characteristics/medical findings were evaluated by slit-lamp microscopy; the findings and percentages in the two groups were similar. Findings included blepharitis/meibomianitis, controlled diabetes without retinopathy, dry eye, lids/adnexa (dermatochalasis, trichiasis, and ptosis), vitreous detachment and/or floaters, corneal findings, and retina findings.

3.2. Questionnaire Results. The primary endpoint related to “the overall performance of the OVD” was obtained from the investigator questionnaire using a 5-point scale (1 = unacceptable, 3 = acceptable, and 5 = excellent). The rates of user acceptance (“acceptable-excellent”) were 93.2% for the Healon PRO OVD and 95.7% for the Healon OVD (Figures 1 and 2).

The null hypothesis was that the user acceptance rate of the Healon PRO OVD would be 15% worse than or equal to that of the Healon OVD. The success criterion is defined as having the lower 2-sided 90% confidence interval of the difference in ratings between OVDs be greater than −15%. The difference in user acceptance rates between the two groups was −2.59% (90% CI, −8.85% to 3.72%). The lower CI of the difference was −8.85%, which was higher than the noninferiority margin of −15%; thus, the null hypothesis was rejected, and it was concluded that the Healon PRO OVD was not statistically noninferior in the overall clinical performance compared to the Healon OVD.

The investigator questionnaire also provided data on the following variables: Ease of injectability was given high ratings by the surgeons for both OVDs, with a majority of the responses rated as “excellent”: 89.0% for the Healon PRO OVD and 72.9% for the Healon OVD (Figure 3). There was a statistically significant difference between OVD groups, favouring the Healon PRO OVD (p = 0.0134). The p values for the questionnaire endpoints are from the two-sided Wilcoxon rank sum test.

Quantity of bubbles was rated as “excellent” in most instances for both OVDs: 84.9% for the Healon PRO OVD and 77.1% for the Healon OVD (control) (Figure 4). Because bubbles obscure the surgeon’s view, having a smaller quantity of bubbles was preferred. There was no statistically significant difference in the quantity of bubbles (p = 0.224) between the two OVDs.

Transparency/visibility was rated as “excellent” in a majority of cases for both OVDs: 91.8% for the Healon PRO OVD and 80.0% for the control (Figure 5). There was a statistically significant preference in transparency/visibility for the Healon PRO OVD when compared to the Healon OVD (p = 0.049).

Tissue manipulation ratings were high for both OVDs, with over 95% of ratings being acceptable (Figure 6). There was no statistically significant difference in the scores between the two groups for tissue manipulation (p = 0.119).

Ease of IOL placement was rated “excellent” in 90% of the ratings for the Healon PRO OVD, with a statistically significant improvement in ease of IOL placement between the OVD groups favouring the Healon PRO OVD (p = 0.029) (Figure 7).

Ease of removal was rated acceptable in all cases for both OVDs, with a majority being rated “excellent” (Figure 8). There was no statistically significant difference in the ease of removal (p = 0.574).

3.3. Other Endpoints. The rate of IOP spike, defined as 30 mmHg or greater at 1 day postoperatively, revealed no statistically significant difference (p = 0.999) (from two-sided Fisher’s exact test). The IOP spike rates for the Healon PRO OVD and Healon OVD were 5.5% and 4.3%, respectively.
The mean differences in IOP from baseline to 1 day postoperatively were 3.2 mmHg (95% CI, 1.8 to 4.6) for the Healon PRO OVD and 2.0 mmHg (95% CI, 0.9 to 3.2) for the Healon OVD (Figure 9). The mean difference between OVDs was −1.1 mmHg (95% CI, −3.0 to 0.7), with no statistically significant difference in the change of IOP between the Healon PRO OVD and Healon OVD (p = 0.219 from two-sided two-sample t-test).

3.4. Ancillary Analyses. Surgical complications were rare, with only one complication (1.4%, 1/73) of zonular damage/rupture occurring in the Healon OVD group and one complication (1.4%, 1/70) of vitreous loss occurring in the Healon PRO OVD group. No surgical procedures outside of the protocol were performed.

The most common adverse event reported was elevated IOP, and this was similar between groups: 6.8% (5/73) in the Healon PRO OVD group and 4.3% (3/70) for the Healon OVD control group.

4. Discussion

Viscoelastics are indicated for use as a surgical aid in anterior segment procedures [1–3, 4] and have an important protective role in minimising corneal trauma [5–11]. This clinical study compared the clinical performance of the two OVDs under normal use conditions during the cataract
surgical procedure and addresses the trend of moving from animal- to bacterially derived sodium hyaluronate for use in OVDs.

This 2 day, prospective, multicenter, randomized, participant/evaluator-masked clinical investigation evaluated the acceptability of the bacterially derived Healon PRO OVD when compared to the animal-derived Healon OVD control under normal use conditions during the cataract surgical procedure. The primary hypothesis was that the overall clinical performance of the test product would be evaluated by the surgeon to be statistically noninferior to the control group. The results show that the Healon PRO OVD was
statistically noninferior to the Healon OVD in the ratings for the overall clinical performance, and thus, the primary hypothesis was achieved and the null hypothesis rejected. Whilst the rates of user acceptance ("acceptable"–"excellent") were high for both the Healon PRO OVD and for Healon OVD, with a majority of the ratings being "excellent," these results indicate that the Healon PRO OVD is an appropriate alternative to the animal-derived Healon OVD.

The use of viscoelastics aids the manipulation of surgical tissue [12–14] and contributes to the stability of postoperative IOP [15–21]. The Healon PRO OVD showed
in the EU, and all of the participants were Caucasian, thus limiting intersubject variety.

In conclusion, this study has demonstrated that the overall clinical performance of the Healon PRO OVD was noninferior to that of the Healon OVD. All study endpoints were achieved, and results were comparable between OVD groups. Hence, the results of this clinical investigation support the safety and effectiveness of the bacterially derived, marketed Healon PRO OVD.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that JM. Larrosa, L. Daas, A. Gavin, C. Isanta, A. Langenbucher, B. Jackson, and B. Seitz have no financial interest in the products mentioned in this article. R. Guerrero, L. Tsai, and D. P. Janakiraman are employees of Johnson & Johnson Surgical Vision, Inc.

Acknowledgments

This study was funded by Johnson & Johnson Surgical Vision, Inc., 1700E St. Andrew Place, Santa Ana, CA 92705, USA. This study is registered with DRKS Data Management (DRKS00016742).

References

[1] T. J. Liesegang, “Viscoelastic substances in ophthalmology,” Survey of Ophthalmology, vol. 34, no. 4, pp. 268–293, 1990.
[2] J. Colin, L. Durand, M. Mouillon et al., “Comparative clinical trial of AMO Vitrax and Healon use in extracapsular cataract extraction,” Journal of Cataract & Refractive Surgery, vol. 21, no. 2, pp. 196–201, 1995.
[3] D. H. Chang, W. C. Christie, J. C. Loden, P. J. Smith, and B. E. Jackson, “Clinical evaluation of a bacterially derived sodium hyaluronate 2.3% ophthalmic viscosurgical device,” Journal of Cataract and Refractive Surgery, vol. 45, no. 12, pp. 1789–1796, 2019.
[4] T. Oshika, H. Bissen-Miyajima, Y. Fujita et al., “Prospective randomized comparison of DisCoVisc and Healon5 in phacoemulsification and intraocular lens implantation,” Eye, vol. 24, no. 8, pp. 1376–1381, 2010.
[5] J. J. Durand, M. Kosunick, and M. A. Bullimore, “Reliability of corneal thickness and endothelial cell density measures,” Journal of Refractive Surgery, vol. 19, pp. 344–352, 2003.
[6] A. Baradaran-Rafii, M. Rahmati-Kamel, M. Eslani, V. Kiavash, and F. Karimian, “Effect of hydrodynamic parameters on corneal endothelial cell loss after phacoemulsification,” Journal of Cataract & Refractive Surgery, vol. 35, no. 4, pp. 732–737, 2009.
[7] W. M. Bourne and H. E. Kaufman, “Endothelial damage associated with intraocular lenses,” American Journal of Ophthalmology, vol. 81, no. 4, pp. 482–485, 1976.
[8] M. T. Craig, R. J. Olson, N. Mamalis, and R. J. Olson, “Air bubble endothelial damage during phacoemulsification in human eye bank eyes: the protective effects of Healon and
Viscoat,” *Journal of Cataract & Refractive Surgery*, vol. 16, no. 5, pp. 597–602, 1990.

[9] K. Hayashi, H. Hayashi, F. Nakao, and F. Hayashi, “Risk factors for corneal endothelial injury during phacoemulsification,” *Journal of Cataract & Refractive Surgery*, vol. 22, no. 8, pp. 1079–1084, 1996.

[10] K. Miyata, S. Maruoka, M. Nakahara et al., “Corneal endothelial cell protection during phacoemulsification: low-versus high-molecular-weight sodium hyaluronate,” *Journal of Cataract & Refractive Surgery*, vol. 28, no. 9, pp. 1557–1560, 2002.

[11] A. Y. Nemet, E. I. Assia, D. Meyerstein, N. Meyerstein, A. Gedanken, and M. Topaz, “Protective effect of free-radical scavengers on corneal endothelial damage in phacoemulsification,” *Journal of Cataract & Refractive Surgery*, vol. 33, no. 2, pp. 310–315, 2007.

[12] G. U. Auffarth, “Removal times and techniques of a viscoadaptive ophthalmic viscosurgical device,” *Journal of Cataract & Refractive Surgery*, vol. 30, no. 4, pp. 879–883, 2004.

[13] S. A. Holzer and E. Wong, “Understanding, retaining, and removing dispersive and pseudodispersive ophthalmic viscosurgical devices,” *Journal of Cataract & Refractive Surgery*, vol. 29, no. 12, pp. 2318–2323, 2003.

[14] T. Oshika, F. Okomoto, Y. Kaji et al., “Retention and removal of a new viscous dispersive ophthalmic viscosurgical device during cataract surgery in animal eyes,” *British Journal of Ophthalmology*, vol. 90, no. 4, pp. 485–487, 2006.

[15] G. Rainer, K. E. Schmidt, O. Findl et al., “Natural course of intraocular pressure after cataract surgery with sodium hyaluronate 1% versus hydroxypropylmethylcellulose 2%,” *Ophthalmology*, vol. 114, no. 6, pp. 1089–1093, 2007.

[16] O. Schwenn, H. B. Dick, F. Krummenauer, S. Christmann, A. Vogel, and N. Pfeiffer, “Healon5 versus Viscoat during cataract surgery: intraocular pressure, laser flare and corneal changes,” *Graefe’s Archive for Clinical and Experimental Ophthalmology*, vol. 238, no. 10, pp. 861–867, 2000.

[17] S. A. Arshinoff, D. A. Albiani, and J. Taylor-Laporte, “Intraocular pressure after bilateral cataract surgery using Healon, Healon5, and Healon GV,” *Journal of Cataract & Refractive Surgery*, vol. 28, no. 4, pp. 617–625, 2002.

[18] M. P. Holzer, M. R. Tetz, G. U. Auffarth, R. Welt, and H.-E. Völcker, “Effect of Healon5 and 4 other viscoelastic substances on intraocular pressure and endothelium after cataract surgery,” *Journal of Cataract & Refractive Surgery*, vol. 27, no. 2, pp. 213–218, 2001.

[19] G. Rainer, R. Menapace, O. Findl et al., “Intraocular pressure rise after small incision cataract surgery: a randomised intraindividual comparison of two dispersive viscoelastic agents,” *British Journal of Ophthalmology*, vol. 85, no. 2, pp. 139–142, 2001.

[20] G. Rainer, R. Menapace, O. Findl, M. Georgopoulos, B. Kiss, and V. Pettnerl, “Intraocular pressure after small incision cataract surgery with Healon5 and Viscoat,” *Journal of Cataract & Refractive Surgery*, vol. 26, no. 2, pp. 271–276, 2000.

[21] G. Rainer, R. Menapace, K. E. Schmied et al., “Natural course of intraocular pressure after cataract surgery with sodium chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat),” *Ophthalmology*, vol. 112, no. 10, pp. 1714–1718, 2005.